These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21395631)

  • 41. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease.
    Saryusz-Wolska M; Szymańska-Garbacz E; Jabłkowski M; Białkowska J; Pawłowski M; Kwiecińska E; Omulecka A; Borkowska A; Ignaczak A; Loba J; Czupryniak L
    Pol Arch Med Wewn; 2011 Mar; 121(3):61-6. PubMed ID: 21430606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study.
    Yari Z; Rahimlou M; Eslamparast T; Ebrahimi-Daryani N; Poustchi H; Hekmatdoost A
    Int J Food Sci Nutr; 2016 Jun; 67(4):461-9. PubMed ID: 26983396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of garlic powder supplementation on insulin resistance, oxidative stress, and body composition in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial.
    Sangouni AA; Mohammad Hosseini Azar MR; Alizadeh M
    Complement Ther Med; 2020 Jun; 51():102428. PubMed ID: 32507439
    [TBL] [Abstract][Full Text] [Related]  

  • 47. More Frequent Clinic Visits Are Associated with Improved Outcomes for Children with NAFLD.
    Lam C; Bandsma R; Ling S; Mouzaki M
    Can J Gastroenterol Hepatol; 2016; 2016():8205494. PubMed ID: 28058253
    [No Abstract]   [Full Text] [Related]  

  • 48. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
    Safadi R; Braun M; Francis A; Milgrom Y; Massarwa M; Hakimian D; Hazou W; Issachar A; Harpaz Z; Farbstein M; Itzhak I; Lev-Cohain N; Bareket-Samish A; Silverman MH; Fishman P
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1405-1415. PubMed ID: 34671996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
    Kim W; Kim BG; Lee JS; Lee CK; Yeon JE; Chang MS; Kim JH; Kim H; Yi S; Lee J; Cho JY; Kim SG; Lee JH; Kim YJ
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1073-1083. PubMed ID: 28225186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vegan Diet Advice Might Benefit Liver Enzymes in Nonalcoholic Fatty Liver Disease: an Open Observational Pilot Study.
    Chiarioni G; Popa SL; Dalbeni A; Senore C; Leucuta DC; Baroni L; Fantin A
    J Gastrointestin Liver Dis; 2021 Mar; 30(1):81-87. PubMed ID: 33548123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study.
    Seko Y; Yamaguchi K; Umemura A; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Moriguchi M; Okanoue T; Itoh Y
    Hepatol Res; 2020 Dec; 50(12):1328-1336. PubMed ID: 32926754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-alcoholic fatty liver disease and flavonoids: Current perspectives.
    Shin JH; Jung JH
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):17-24. PubMed ID: 27545758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating nonalcoholic steatohepatitis in children: Not a cinch task.
    Alkhouri N; Feldstein AE
    Hepatology; 2017 Apr; 65(4):1407-1409. PubMed ID: 28073147
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of Pomegranate and Orange Juice on Antioxidant Status in Non-Alcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial.
    Ekhlasi G; Shidfar F; Agah S; Merat S; Hosseini AF
    Int J Vitam Nutr Res; 2015 Dec; 85(5-6):292-298. PubMed ID: 27414418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study.
    Merat S; Malekzadeh R; Sohrabi MR; Hormazdi M; Naserimoghadam S; Mikaeli J; Farahvash MJ; Ansari R; Sotoudehmanesh R; Khatibian M
    J Clin Gastroenterol; 2003 Mar; 36(3):266-8. PubMed ID: 12590240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Non alcoholic fatty liver disease: treatment with soluble fibres].
    Rocha R; Cotrim HP; Siqueira AC; Floriano S
    Arq Gastroenterol; 2007; 44(4):350-2. PubMed ID: 18317656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in alanine aminotransferase in adults with severe and complicated obesity during a milk-based meal replacement programme.
    Abdalgwad R; Rafey MF; Murphy C; Ioana I; O'Shea PM; Slattery E; Davenport C; O'Keeffe DT; Finucane FM
    Nutr Metab (Lond); 2020; 17():87. PubMed ID: 33072167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treating pediatric nonalcoholic fatty liver disease with cysteamine: is adiponectin the key?
    Xanthakos SA; Kohli R
    J Pediatr; 2012 Oct; 161(4):579-81. PubMed ID: 22738945
    [No Abstract]   [Full Text] [Related]  

  • 59. Cysteamine dose regimen.
    Ehrich JH
    Pediatr Nephrol; 2006 Aug; 21(8):1213; author reply 1214. PubMed ID: 16850308
    [No Abstract]   [Full Text] [Related]  

  • 60. Erratum: The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules [Corrigendum].
    Drug Des Devel Ther; 2018; 12():3797. PubMed ID: 30464410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.